• Ingeborg Dhooge, Catharina Dhooge, Sven Geukens, Bieke De Clerck, Eddy De Vel, and Bart M Vinck.
• ENT Department, Department of Pediatric Hematology and Oncology, Ghent University Hospital, Ghent, Belgium. ingeborg.dhooge@ugent.be
• Int J Audiol. 2006 Jun 1; 45 (6): 337-43.

AbstractIn order to develop a sensitive audiometric protocol for identifying ototoxicity in children, a retrospective study of 16 children treated with cisplatin and/or carboplatin was performed. Audiometric testing was done by means of pure-tone threshold audiometry (PTA), high-frequency audiometry (HFA), and distortion product otoacoustic emissions (DPOAEs). Cisplatin caused a sensorineural high-frequency hearing loss in the study group compared to the controls (p < 0.01). Sixty-six percent of the cisplatin patients had a grade 2 or 3 ototoxicity. However, ototoxicity was not found in the patients treated with carboplatin. An excellent correlation was found between DPOAE levels and results obtained by audiometry (r = 0.82). Patients exposed to cisplatin are at significant risk for the development of drug-induced sensorineural hearing loss. Because of the several advantages of DPOAEs (noninvasive, objective, rapid, easy to use, sensitive) this method should be added in the audiological follow-up in infants and toddlers.

33 keywords...

hide…